Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin

  • Sungjin Chung,
  • Soojeong Kim,
  • Minyoung Kim,
  • Eun Sil Koh,
  • Seok Joon Shin,
  • Cheol Whee Park,
  • Yoon Sik Chang,
  • Ho-Shik Kim

There are errors in Figs 1 and 3. The authors have provided corrected versions here.

thumbnail
Download:
Fig 1. Greater beneficial effect of combination treatment with aliskiren and paricalcitol on renal fibrosis in the obstructed kidney.

(A) Representative renal sections stained with Masson-trichrome (original magnifications, x200). (B) Quantitative analysis of the results for fibrotic area in the renal tubulointerstitium. *P<0.001 versus UUO; **P = 0.001 versus UUO; #P<0.001 versus UUO+A or UUO+P.

https://doi.org/10.1371/journal.pone.0196885.g001

thumbnail
Download:
Fig 3. Synergistic effect of combination treatment with aliskiren and paricalcitol on the expression of myofibroblasts in the obstructed kidney.

(A) Representative renal sections stained with α-SMA(original magnification, x200). (B) Quantitative analysis of the results for α-SMA in the renal tubulointerstitium. *P<0.001 versus UUO; **P = 0.001 versus UUO; #P = 0.001 versus UUO+A and P<0.001 versus UUO+P. α-SMA, α-smooth muscle actin.

https://doi.org/10.1371/journal.pone.0196885.g002

Reference

  1. 1. Chung S, Kim S, Kim M, Koh ES, Shin SJ, Park CW, et al. (2017) Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. PLoS ONE 12(7): e0181757. https://doi.org/10.1371/journal.pone.0181757 pmid:28753620

Citation: Chung S, Kim S, Kim M, Koh ES, Shin SJ, Park CW, et al. (2018) Correction: Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. PLoS ONE 13(5): e0196885. https://doi.org/10.1371/journal.pone.0196885

Published: May 1, 2018

Copyright: © 2018 Chung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.